RecruitingPhase 2NCT06617481
PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
RhPSMA-7.3(18F)-PET Scan to Detect Prostate Cancer in Patients with Early PSA Recurrence
Sponsor
AdventHealth
Enrollment
30 participants
Start Date
Sep 20, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.
Eligibility
Sex: MALEMin Age: 18 Years
Inclusion Criteria2
- History of localized adenocarcinoma of the prostate with prior curative intent radical prostatectomy.
- An elevated PSA test result that is greater than or equal to 0.1 ng/ml and less than 0.5
Exclusion Criteria2
- Patients who are planned to have an x-ray contrast agent or other PET radiotracer \& less than 24 hours prior to the flotufolastat F-18 PSMA-PET scan.
- Patients currently receiving Androgen Deprivation Therapy (ADT).
Interventions
DRUG18F-rhPSMA-7.3 (Posluma)
PET Scan using Posluma for detection of early recurrence of prostate cancer.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06617481
Related Trials
Effect of Education to be Provided to Patients to Undergo TURP With Mobile Application on Patient Outcomes
NCT066875381 location
Salvage Ultrahypofractionated Postoperative External Radiotherapy For Biochemical Recurrence
NCT069413631 location
Adaptive Radiotherapy for Genitourinary Cancers
NCT073247981 location
The Effect of a Structured Strength and Endurance Training Program on Quality of Life, Fitness, Blood Parameters and Survival in Prostate Cancer Patients
NCT071268601 location
Effects of Hypopressive Exercises on Urinary Incontinence and Erectile Dysfunction After Radical Prostatectomy
NCT071017311 location